GoldhirschA., WoodW.C., GelberR.D.: Meeting highlights: updated international export consensus on the primary therapy of early breast cancer.J Clin Oncol,21: 3357–3365, 2003.
2.
HendersonI.C., BerryD.A., DemetriG.D.: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.J Clin Oncol,21: 976–983, 2003.
3.
MamounasE.P., BryantJ., LemberskyC.: Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP-B28.Proc ASCO,22: 4 (Abst 12), 2003.
4.
KaufmannM., von MinckwitzG., SmithR.: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.J Clin Oncol,21: 2600–2608, 2003.
5.
EiermannW., PaepKeS., AppfelstaedtJ.: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study.Ann Oncol,12: 1527–1532, 2001.
6.
CitronC.L., BerryD.A., CirrincioneC.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group 9741.J Clin Oncol,21: 14131–1439, 2003.
7.
VenturiniM., AitiniE., Del MastroL.: Phase III adjuvant trial comparing standard versus accelerated FEC regimen in early breast cancer patients. Results from GONO-MIG-1 study.Breast Cancer Res Treat,82: S9 (abst), 2003.
8.
RiggsB.L., HartmannL.C.: Selective estrogen-receptor modulators: mechanisms of action and application to clinical practice.N Engl J Med,348: 618–629, 2003.
9.
JordanV.C.: Is tamoxifen the Rosetta stone for breast cancer?J Natl Cancer Inst,95: 338–340, 2003.
10.
OsborneC.K., BardouV., HoppT.A.: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER2-neu in tamoxifen resistance in breast cancer.J Natl Cancer Inst,95: 353–361, 2003.
11.
De PlacidoS., De LaurentiisM., CarlomagnoC.: Twenty-year results of the Naples GUN randomized trial: predictive factor of adjuvant tamoxifen efficacy in early breast cancer.Clin Cancer Res,9: 1039–1046, 2003.
12.
EllisM.J., CoopA., SinghB.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for Erb-1 and/or ErbB-2 positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.J Clin Oncol,19: 3808–3816, 2001.
13.
LoveR.R., DucN.B., HavighurstT.C.: Her2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.J Clin Oncol,21: 453–457, 2003.
